WO2024230578 - CYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2024/230578
Publication Date
14.11.2024
International Application No.
PCT/CN2024/090758
International Filing Date
30.04.2024
Title **
[English]
CYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF
[French]
DÉRIVÉS CYCLIQUES, COMPOSITIONS ET UTILISATIONS DE CEUX-CI
Applicants **
DANATLAS PHARMACEUTICALS CO., LTD.
Suite 101, Floor 2, Building 2-4A, 7#, Liangshuihe 1st Street, BDA
Daxing District, Beijing 100176, CN
Inventors
ZHOU, Wenlai
Suite 101, Floor 2, Building 2-4A, 7#, Liangshuihe 1st Street, BDA
Daxing District, Beijing 100176, CN
ZHUO, Jincong
Suite 101, Floor 2, Building 2-4A, 7#, Liangshuihe 1st Street, BDA
Daxing District, Beijing 100176, CN
ZHANG, Yao
Suite 101, Floor 2, Building 2-4A, 7#, Liangshuihe 1st Street, BDA
Daxing District, Beijing 100176, CN
Priority Data
PCT/CN2023/092300
05.05.2023
CN
PCT/CN2023/102459
26.06.2023
CN
PCT/CN2023/122431
28.09.2023
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CNIPA
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2450 | |
| EPO | Filing, Examination | 16293 | |
| Japan | Filing | 531 | |
| South Korea | Filing | 640 | |
| USA | Filing, Examination | 13685 |
Total: 33599 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The disclosure relates to cyclic derivatives as shown in Formula (I), to pharmaceutical compositions comprising them, to a process for their preparation, and their use as therapeutic agents.[French]
L'invention concerne des dérivés cycliques tels que représentés dans la formule (I), des compositions pharmaceutiques les comprenant, un procédé pour leur préparation, et leur utilisation en tant qu'agents thérapeutiques.